Rafael Caparica1, Yaohua Ma2, Claudia De Angelis3, François Richard4, Christine Desmedt4, Ahmad Awada5, Martine Piccart5, Edith A Perez6, Alvaro Moreno-Aspitia6, Sunil Badve7, E Aubrey Thompson8, Evandro de Azambuja5. 1. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. Electronic address: rcaparica@hotmail.com. 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL. 3. Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Pisa, Italy. 4. Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Belgium. 5. Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium. 6. Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL. 7. Department of Pathology, Indiana University School of Medicine, IN. 8. Department of Cancer Biology, Mayo Clinic, Jacksonville, FL.
Abstract
BACKGROUND: Beta-2 adrenergic receptor (ß2AR) modulates immune activation and may enhance trastuzumab activity. We assessed the impact of ß2AR gene (ADRB2) expression on the outcomes of patients with HER2-positive early-stage breast cancer enrolled on the NCCTG-N9831 trial. PATIENTS AND METHODS: This is a post-hoc analysis of the NCCTG-N9831 trial, which compared chemotherapy (arm A) versus chemotherapy plus trastuzumab (arms B&C) as adjuvant treatment of patients with HER2-positive early-stage breast cancer, with disease-free survival (DFS) as primary endpoint. Gene expression levels retrieved by DASL assay were used to classify patients as ADRB2-high or ADRB2-low. Hazard ratios (HRs) were calculated by a Cox proportional model adjusted for prognostic variables and ADRB2 expression. Correlations between ADRB2 expression and stromal tumor-infiltrating lymphocyte (TIL) levels were assessed with Pearson coefficient. A multivariable Cox regression model with interaction term was performed to assess the interaction between ADRB2 expression and treatment arm; and ADRB2 expression and a 8-gene signature previously shown to predict trastuzumab benefit. RESULTS: Overall, 1,282 patients were included (ADRB2-high [N = 944] / ADRB2-low [N = 338]). A high expression of ADRB2 was associated with a longer DFS (P = .01) in the overall population. The addition of trastuzumab to chemotherapy improved DFS only in patients with ADRB2-high tumors (P < .01). ADRB2 expression was correlated with TIL levels (r = 0.24, P < .001). No association between ADRB2 expression and the 8-gene trastuzumab benefit signature was observed (P = .32). CONCLUSION: Our findings suggest that a high ADRB2 expression is a favorable prognostic factor and may identify patients with HER2-positive early-stage breast cancer who benefit from adjuvant trastuzumab. TRIAL REGISTRATION: clinicaltrials.gov NCT00005970.
BACKGROUND: Beta-2 adrenergic receptor (ß2AR) modulates immune activation and may enhance trastuzumab activity. We assessed the impact of ß2AR gene (ADRB2) expression on the outcomes of patients with HER2-positive early-stage breast cancer enrolled on the NCCTG-N9831 trial. PATIENTS AND METHODS: This is a post-hoc analysis of the NCCTG-N9831 trial, which compared chemotherapy (arm A) versus chemotherapy plus trastuzumab (arms B&C) as adjuvant treatment of patients with HER2-positive early-stage breast cancer, with disease-free survival (DFS) as primary endpoint. Gene expression levels retrieved by DASL assay were used to classify patients as ADRB2-high or ADRB2-low. Hazard ratios (HRs) were calculated by a Cox proportional model adjusted for prognostic variables and ADRB2 expression. Correlations between ADRB2 expression and stromal tumor-infiltrating lymphocyte (TIL) levels were assessed with Pearson coefficient. A multivariable Cox regression model with interaction term was performed to assess the interaction between ADRB2 expression and treatment arm; and ADRB2 expression and a 8-gene signature previously shown to predict trastuzumab benefit. RESULTS: Overall, 1,282 patients were included (ADRB2-high [N = 944] / ADRB2-low [N = 338]). A high expression of ADRB2 was associated with a longer DFS (P = .01) in the overall population. The addition of trastuzumab to chemotherapy improved DFS only in patients with ADRB2-high tumors (P < .01). ADRB2 expression was correlated with TIL levels (r = 0.24, P < .001). No association between ADRB2 expression and the 8-gene trastuzumab benefit signature was observed (P = .32). CONCLUSION: Our findings suggest that a high ADRB2 expression is a favorable prognostic factor and may identify patients with HER2-positive early-stage breast cancer who benefit from adjuvant trastuzumab. TRIAL REGISTRATION: clinicaltrials.gov NCT00005970.
Authors: Rim S Kim; Nan Song; Patrick G Gavin; Roberto Salgado; Hanna Bandos; Zuzana Kos; Giuseppe Floris; Gert G G M Van den Eynden; Sunil Badve; Sandra Demaria; Priya Rastogi; Louis Fehrenbacher; Eleftherios P Mamounas; Sandra M Swain; D Lawrence Wickerham; Joseph P Costantino; Soonmyung Paik; Norman Wolmark; Charles E Geyer; Peter C Lucas; Katherine L Pogue-Geile Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506
Authors: Carsten Denkert; Gunter von Minckwitz; Silvia Darb-Esfahani; Bianca Lederer; Barbara I Heppner; Karsten E Weber; Jan Budczies; Jens Huober; Frederick Klauschen; Jenny Furlanetto; Wolfgang D Schmitt; Jens-Uwe Blohmer; Thomas Karn; Berit M Pfitzner; Sherko Kümmel; Knut Engels; Andreas Schneeweiss; Arndt Hartmann; Aurelia Noske; Peter A Fasching; Christian Jackisch; Marion van Mackelenbergh; Peter Sinn; Christian Schem; Claus Hanusch; Michael Untch; Sibylle Loibl Journal: Lancet Oncol Date: 2017-12-07 Impact factor: 41.316
Authors: Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga Journal: N Engl J Med Date: 2017-06-05 Impact factor: 91.245
Authors: Katherine L Pogue-Geile; Chungyeul Kim; Jong-Hyeon Jeong; Noriko Tanaka; Hanna Bandos; Patrick G Gavin; Debora Fumagalli; Lynn C Goldstein; Nour Sneige; Eike Burandt; Yusuke Taniyama; Olga L Bohn; Ahwon Lee; Seung-Il Kim; Megan L Reilly; Matthew Y Remillard; Nicole L Blackmon; Seong-Rim Kim; Zachary D Horne; Priya Rastogi; Louis Fehrenbacher; Edward H Romond; Sandra M Swain; Eleftherios P Mamounas; D Lawrence Wickerham; Charles E Geyer; Joseph P Costantino; Norman Wolmark; Soonmyung Paik Journal: J Natl Cancer Inst Date: 2013-11-21 Impact factor: 13.506
Authors: Tony Warne; Rouslan Moukhametzianov; Jillian G Baker; Rony Nehmé; Patricia C Edwards; Andrew G W Leslie; Gebhard F X Schertler; Christopher G Tate Journal: Nature Date: 2011-01-13 Impact factor: 49.962